Wall Street analyst estimates for Immuneering Corporation (IMRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.29 | ||
| 2026-08-05 | $-0.27 | $-0.26 | -2.2% |
| 2026-05-15 | $-0.21 | $-0.30 | +30.0% |
| 2026-03-06 | $-0.18 | $-0.31 | +41.9% |
| 2025-11-12 | $-0.38 | $-0.37 | -2.7% |
| 2025-08-13 | $-0.40 | $-0.40 | +0.0% |
| 2025-05-05 | $-0.42 | $-0.41 | -2.4% |
| 2025-03-20 | $-0.58 | $-0.42 | -38.1% |
Valuation Ratios
| Price / Book | 1.50 |
| EV / EBITDA | -2.24 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.3M | $2.1M | $316952 | 0 | 0 | 0 |
| Cost of Revenue | $1.2M | $1.3M | $1.2M | $158122 | 0 | 0 | $698887 |
| Gross Profit | $696739 | $1.0M | $926888 | $158830 | 0 | 0 | -$698887 |
| Research & Development | $4.3M | $15.0M | $26.5M | $36.3M | $41.6M | $48.0M | $42.0M |
| Selling, General & Admin | $2.7M | $3.1M | $8.3M | $15.6M | $16.8M | $16.1M | $17.3M |
| Operating Expenses | $7.0M | $18.1M | $34.8M | $51.9M | $58.4M | $64.1M | $58.7M |
| Operating Income | -$6.3M | -$17.1M | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| EBITDA | -$7.3M | -$17.0M | -$33.7M | -$51.5M | -$58.1M | -$63.7M | -$55.3M |
| Interest Expense | $351302 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$7.7M | -$17.1M | -$33.8M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Income Tax | 0 | -$84336 | -$307485 | 0 | 0 | 0 | 0 |
| Net Income | -$7.7M | -$17.0M | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| EPS | $-0.60 | $-1.26 | $-1.27 | $-1.87 | $-1.88 | $-2.04 | $-1.27 |
| EPS (Diluted) | $-0.60 | $-1.26 | $-1.27 | $-1.87 | $-1.88 | $-2.04 | $-1.27 |
| Shares Outstanding (Diluted) | $13.5M | $13.5M | $26.3M | $26.4M | $28.4M | $30.0M | $44.0M |
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks